The appellate decision is a warm-up act for the Supreme Court, expected to announce shortly that it will decide whether requiring individuals to obtain health insurance is constitutional.
Medscape Medical News
Daily Archives: 2011/11/08
Laser therapy to turn brown eyes blue
A laser treatment developed by Stroma Medical's Dr. Gregg Homer takes only 20 seconds to perform but can turn brown eyes into blue ones permanently.
Back from the AAO
Amy and I got back from Orlando, last week. We attended the American Academy of Ophthalmology annual meeting, the world’s largest gathering of ophthalmologists and those associated with our “industry.” It’s our huge trade show. For us, we got some national exposure for our new company.
Telling a Story
You may remember that we received a nice endorsement from the AAO earlier in the year. The endorsement (Read more...)
SMC accepts ranibizumab (Lucentis®) for restricted use in the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium has accepted ranibizumab (Lucentis®) for restricted use within NHS Scotland for the treatment of adults with macular oedema secondary to central retinal vein occlusion (CRVO). The Drug Advice discusses the evidence considered by the SMC (please see the link below for details). This notes that ranibizumab treatment was associated with significant improvements in visual acuity in one study of patients with branch retinal vein occlusion (BRVO) and in one study of patients with central retinal vein occlusion (CRVO). The acceptance of ranibizumab for use in the treatment of CRVO takes into account a Patient Access Scheme (PAS) and the advice is contingent upon its continuing availability. The drug advice notes that the benefits seen in the clinical study were considerable and that there is a lack of alternative treatment options for this group of patients. The SMC has not accepted the use of ...
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium has accepted ranibizumab (Lucentis®) for restricted use within NHS Scotland for the treatment of adults with macular oedema secondary to central retinal vein occlusion (CRVO). The Drug Advice discusses the evidence considered by the SMC (please see the link below for details). This notes that ranibizumab treatment was associated with significant improvements in visual acuity in one study of patients with branch retinal vein occlusion (BRVO) and in one study of patients with central retinal vein occlusion (CRVO). The acceptance of ranibizumab for use in the treatment of CRVO takes into account a Patient Access Scheme (PAS) and the advice is contingent upon its continuing availability. The drug advice notes that the benefits seen in the clinical study were considerable and that there is a lack of alternative treatment options for this group of patients. The SMC has not accepted the use of ...
Making Medicare Preventive Services Part of Your Practice
iTunes conversion to RSS provided by Feed Flipper: [Web] - [Facebook] - [Donate!]
During annual visits, make time to plan necessary screening and review the patient's overall health needs.
During annual visits, make time to plan necessary screening and review the patient's overall health needs.
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
Status: Completed,
Condition Summary: Age-Related Maculopathy; Age-Related Maculopathies; Eye Diseases; Retinal Degeneration; Macular Degeneration
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
Status: Recruiting,
Condition Summary: Dry Eye Disease
Subscribe
